Table 1 Population characteristics
From: A single-center experience with pancreatic cystic neuroendocrine tumors
Variables | All (n = 106) | C-PNETs (n = 12) | M-PNETs (n = 21) | S-PNETs (n = 73) | P value (C Vs S) | P value (C Vs M) | P value (M Vs S) |
|---|---|---|---|---|---|---|---|
Sexe, female (%) | 64 (60.4) | 7 (58.3) | 14 (66.7) | 43 (58.9) | Ns | Ns | Ns |
Weight, median [min-max] | 67 [10-99] | 74 [45-95] | 71.50 [45-85] | 64.5 [10-99] | Ns | Ns | Ns |
Size (m), median [min-max] | 1.7 [1.4-1.9] | 1.68 [1.5-1.8] | 1.7 [1.5-1.8] | 1.7 [1.4-1.9] | Ns | Ns | Ns |
BMI > 25% | 36 (37.9) | 8 (66.7) | 9 (42.9) | 19 (26) | 0.005 | Ns | Ns |
Age at surgery > 60 years old (%) | 47 (44.3) | 3 (25) | 10 (47.6) | 34 (46.6) | Ns | Ns | Ns |
Symptoms (%) | 75 (70.8) | 7 (58.3) | 16 (76.2) | 52 (71.2) | Ns | Ns | Ns |
Functional (%) | 11 (10.4) | 0 | 2 (9.5) | 9 (12.3) | Ns | Ns | Ns |
MEN 1 (%) | 8 (7.5) | 2 (16.7) | 2 (9.5) | 4 (5.5) | Ns | Ns | Ns |
VHL (%) | 5 (4.7) | 0 | 0 | 5 (6.8) | Ns | Ns | Ns |
Biopsy (%) | 96 (90.6) | 11 (91.7) | 18 (85.7) | 67 (91.8) | Ns | Ns | Ns |
Imaging | Â | Â | Â | Â | Â | Â | Â |
 Thoraco-abdominal CT-Scan (%) | 104 (98.1) | 12 (100) | 20 (95.2) | 72 (98.6) | Ns | Ns | Ns |
 EUS with fine needle aspiration (%) | 95 (89.6) | 12 (100) | 18 (85.7) | 65 (89.0) | Ns | Ns | Ns |
 Abdominal MRI (%) | 57 (53.8) | 6 (50) | 15 (71.4) | 36 (49.3) | Ns | Ns | Ns |
 68Ga-DOTATATE PET/CT (%) | 8 (7.6) | 0 (0) | 1 (4.8) | 7 (9.6) | Ns | Ns | Ns |
 99mTc-Octreotide SPECT/CT (%) | 37 (34.9) | 4 (33.3) | 7 (33.3) | 26 (35.6) | Ns | Ns | Ns |
Preoperative diagnosis of NET (%) | 82 (77.4) | 4 (33.3) | 13 (61.9) | 65 (89) | < 0.001 | Ns | 0.004 |
Metastasis at staging (%) | 24 (22.6) | 0 | 2 (9.5) | 22 (30.1) | 0.027 | Ns | Ns |
Neo-adjuvent chemotherapy (%) | 8 (7.5) | 0 | 0 | 8 (11) | Ns | Ns | Ns |
Adjuvent chemotherapy (%) | 23 (21.7) | 0 | 3 (14.3) | 20 (27.4) | 0.038 | Ns | Ns |
Neo-adjuvent Sandostatin analog (%) | 6 (5.7) | 0 | 1 (4.8) | 5 (6.8) | Ns | Ns | Ns |